US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson's Disease Treatments [Yahoo! Finance]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Yahoo! Finance
Exton, Pennsylvania, May 09, 2024 (GLOBE NEWSWIRE) -- Even as the incidence of Parkinson's disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape has remained relatively stagnant. Yet, neurologists are hopeful about new ways to deliver levodopa/carbidopa (the current standard of care), new symptomatic treatments, and potential pathways for future disease modifying treatments (DMTs). In the newly published Special Topix™: Novel Treatments in Parkinson's Disease: What's Next in PD After Carbidopa/Levodopa? , Spherix sought to uncover clinical trial endpoints and product profiles that most resonate with treating neurologists. In the near future, neurologists are interested in novel delivery mechanisms such as AbbVie's Produodopa (a subcutaneous levodopa/carbidopa pump) and symptomatic treatments such as Cerevel Therapeutics' tavapadon, meant to reduce the amount of “side-effect” time PD patients experience with levodopa/carbidopa.
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- MERGER UPDATE: BFA Law is Investigating Whether the $45 Per Share Offer for Cerevel Is Too Low and Reminds Shareholders to Contact the FirmAccesswire
- BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by AbbVie, Contact the Firm for DetailsGlobeNewswire
- 1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? [Yahoo! Finance]Yahoo! Finance
- NOTICE OF INVESTIGATION: Kaskela Law LLC Announces Shareholder Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the FirmPR Newswire
- INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair ProcessGlobeNewswire
CERE
Earnings
- 5/8/24 - Miss
CERE
Sec Filings
- 5/14/24 - Form 4
- 5/10/24 - Form 144
- 5/10/24 - Form SC
- CERE's page on the SEC website